Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) reported a shortage of Bicillin L-A (penicillin G benzathine suspension; Pfizer) Injection due to manufacturing delays.
The shortage affects the following formulations:
- Bicillin L-A 600,000U Pediatric Injection
- Bicillin L-A 1,200,000U/2mL
- Bicillin L-A 2,400,000U/4mL
All products are currently on backorder, which is expected to resolve by July 2016. The products are on allocation and inventory should be verified with wholesalers and distributors.
Bicillin L-A is a penicillinase-sensitive penicillin indicated for susceptible infections, including mild to moderate upper respiratory strep infections and syphilis. Benzathine penicillin G is the recommended treatment for syphilis and is the only option for pregnant women infected with or exposed to syphilis. It is also indicated as follow-up prophylaxis of rheumatic heart disease and acute glomerulonephritis.
The Centers for Disease Control and Prevention (CDC) recommend that until the normal stock of Bicillin L-A is available, clinicians should consider prioritizing Bicillin L-A for the treatment of syphilis especially in pregnant women infected with or exposed to syphilis.
For more information call (800) 533-4535 or visit FDA.gov.
